Archive | April, 2015

If You Build It, They Will Come!

30 Apr
By Dennis Ford, Founder & CEO, LSN 

Dennis book

The list below represents the investors who are currently confirmed to attend the RESI @ TMCx conference this June 8th in Houston. This number can be expected to double during the final month leading up to the event. Whether you are just thinking of raising capital in the life science space or have actively begun the process, the RESI conference offers a one-of-a-kind opportunity to get some feedback and build relationships with the investors in your market.

As of April 28, 2015 | Click the image to learn more about the investors

The ROI from attending the RESI conference is pretty dramatic. A fundraising CEO can book up to 16 one-on-one meetings for the day through our partnering software, and more by taking advantage of the networking opportunities that are offered before and during the event. No matter where you are in the fundraising process, RESI @ TMCx is the place to start a dialogue that will hopefully evolve into a compelling relationship and ultimately an allocation.

What makes RESI such a uniquely valuable event for life science entrepreneurs is not only the number of active investors we bring to the table, but also their diversity. RESI has unigue value in that its primary focus is the bringing together 10 categories of investors, including family offices, corporate venture capital, large pharma and biotech, venture capital, and more as depicted in the chart below. This breadth of diverse early stage investor participation makes RESI a great fit for a life science fundraiser seeking any kind of investment, from seed money to series A or B capital to strategic partnership.

RESI @ TMCx Investors

Data as of April 28, 2015

Whether your company was just formed or you are looking for capital to fund your next clinical trial, it is never too early to start a relationship with an investor, and the RESI conference will have a strong showing of those with serious interest in the life science space. All of these investors will be profiled in our partnering software, which goes live next week and helps you schedule a meeting based on mutual fit with just a few clicks. Start the fundraising dialogue now. Register here.

Still have questions? Feel free to email or call our conference manager Natasha Eldridge at n.eldridge@lifesciencenation.com or 617-580-5001; she will be happy to address any concerns you have.

Q1 2015 Life Science Financing Roundup

30 Apr

By Lucy Parkinson, Senior Research Manager, LSN

lucy 10*10

It’s been an exciting Q1 for the biotech industry, with the PwC MoneyTree Report recording 193 biotech and medtech venture financing deals. The LSN Company Platform tracks life science financing events more broadly than the MoneyTree Report; in addition to venture financing rounds, the platform also records other forms of financing secured by the 30,000 biotech and medtech companies tracked, including debt financing, research grants, IPOs, and post-IPO offerings. This is useful information if you’re providing services in the life science sector and need to know your customers’ capital landscape. The platform also records the lead investor and any co-investors in each financing event.

It may be months before all the deals that took place in Q1 are formally announced and accounted for, but at present the LSN Company Platform has recorded 229 life science financing events that took place in Q1 2015. These financings raised a total of almost $10 billion, buoyed by huge late stage private rounds and follow-on public offerings. Among the financing events LSN tracked, the median amount raised was $15 million. Figure 1 provides a complete breakdown of the amount raised by the financing events recorded in Q1:

F1

Figure 1 | Source: LSN Company Platform, Data as of March 31, 2015

 

Q1 saw a healthy crop of small, sub-$5 million rounds, which are typically raised by early stage companies, but also many significantly larger raises, including post-IPO financings in which companies that went public in 2013 and 2014 tapped the markets for additional capital.

While the bulk of the tracked financing events occurred in the U.S., the LSN Company Platform also recorded deals in Canada and throughout Europe, the Middle East, Asia, and Oceania (see Figure 2).

F2

Figure 2 | Source: LSN Company Platform, Data as of March 31, 2015

 

In 157 cases, the LSN Company Platform recorded the indication areas in which the companies are developing assets (in many cases, the companies were targeting more than one indication area). Figure 3 shows that oncology was the leading field for financing, with 62 oncology companies raising money in Q1; companies in diseases of the nervous system and metabolic diseases rounded out the top 3 indications for life science financing.

F3

Figure 3 | Source: LSN Company Platform, Data as of March 31, 2015

 

In 125 of the 229 records, the LSN Company Platform was able to track the phase of development of a company’s lead asset. (The rest include companies for which this isn’t relevant or doesn’t fit on the biotech development pathway, such as life science service providers and many medtech or healthcare IT companies, and cases in which the phase of the lead asset is unknown). As Figure 4 shows, the largest number of raises involved companies with a lead asset in Phase II, but LSN tracked financing events for companies as early in the pipeline as the discovery stage:

F4

Figure 4 | Source: LSN Company Platform, Data as of March 31, 2015

 

This chart demonstrates that it’s never too early to think about financing, even if your company is still at the discovery stage of development. In addition to giving you some vital runway time, talking to investors now can help you plan out your future fundraising path; financing rounds generally take 9 to 18 months to close, and the more interested investors you can be in touch with at the early stage, the easier it will be to bring those later rounds together.

RESI @ TMCx “Healthcare IT Investors” Panel Announcement

30 Apr

By Natasha Eldridge, Marketing Manager, Life Science Nation

natashaThe healthcare IT sector is booming, with $6.5 billion invested in healthcare IT companies in 2014. As the Texas Medical Center taking a lead on supporting healthcare IT companies in the Southwest, RESI @ TMCx will feature a panel session exploring investment in the sector.

LSN has gathered a group of experienced healthcare IT investors to share their expertise and advice with entrepreneurs. These investors focus on the information technology opportunities that underlie healthcare innovation, from the possibilities created by big data to the digitization of healthcare providers and research labs. Panelists will discuss issues related to funding in healthcare IT, such as: How do you make your company stand out in this crowded marketplace? What do investors see as the most high-potential fields of innovation in healthcare IT? How do you demonstrate to an investor that your product has the potential to succeed?

Joining the moderator, David Franklin, Managing Director, Houston Health Ventures will be:

resi5-24final-800-300v2

 

Hot Life Science Investor Mandate 1: Family Office Looking Opportunistically in the Life Science Space

30 Apr

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

The firm is looking for companies with experienced management teams and will seek a board seat on a case by case basis when it is appropriate to do so. The firm is generally more comfortable with co-investing in early stage opportunities although they are not completely opposed to leading a round if the right opportunity were to present itself.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Corporate VC of Large Tech Company Seeking to Invest in Healthcare IT and Imaging Technologies

30 Apr

The corporate venture capital arm of a large tech company is actively seeking investments in the life science space. The firm manages two venture funds worth a total of $1.1B; one of these funds focuses on early-stage companies, and the other targets companies of all sizes.  The firm is actively seeking new investment opportunities and is open to review opportunities from around the globe.

In the Life Sciences, the firm seeks to invest in Mobile healthcare IT, bio authentication, fitness and wellness measurement algorithm (i.e. Fitbit and Basis type of companies), calorie measurement, heart measurement, glucose measurement, and medical imaging equipment technology (i.e. Ultrasound, MRI, CAT scan, and image enhancement and distribution tech). The firm is open to reviewing companies of all stages.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: US-based Hedge Fund Seeking Early Stage Oncology Therapeutics

30 Apr

A venture capital and hedge fund hybrid based in the Western United States is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development; however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: Healthcare Angel Group Seeking Therapeutics Devices and Diagnostics Across the United States

30 Apr

An angel group that is made up entirely of healthcare professionals is seeking to invest in technologies that significantly advance the standard of care. The group considers companies at a range of stages and is geographically agnostic. Since the members are investing their own capital, the investment size and capital structure are highly flexible. The group is actively seeking new investment opportunities, and is open to leading financing rounds.

The group is interested in therapeutics, diagnostics, and medical devices. While the group will consider most any indication and technology type, the group currently has a particular interest in cell therapy and in the oncology sector. In general, the group is not interested in dermatology. The group will only consider products that have shown human clinical efficacy; in the case of therapeutics, the group generally looks at phase II companies but if a company has obtained human efficacy data in phase I, the group would consider the opportunity. 

The group invests in both private and public companies. The group performs deep scientific due diligence on all the opportunities that the group takes part in, often conducted by the group’s members.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com